Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies

Table 5

Most relevant published studies investigating the frequency and the prognostic significance of Tregs in chronic myeloid leukemia.

Reference	Patients/controls evaluated	Samples tested	Marker panel used in Treg evaluation by flow cytometry	Treg frequency	Functional studies	Impact on prognosis
Zahran and Badrawy [62]	CML/controls	PB	CD4/CD25/FoxP3	Increased	Not performed	Correlations with the level of BCR/ABL, basophils and blast cells. Significantly higher in accelerated phase and blastic phase than in chronic phase and with high Sokal score. Reduction of Tregs after therapy with IM
Hus et al. [65]	CP CML/controls	PB	CD4/CD25/FoxP3	Increased	Not performed	Correlation with higher basophiles. No change in frequency after 6 months of TKI inhibitors
Bachy et al. [74]	CP CML/controls	CD4+ enriched PBMC cells	CD4/CD25/CD127/FoxP3	Increased in PB. Increased in BM of patients on IM compared to healthy volunteers.	No difference in inhibition	Correlation with Sokal risk score
Rojas et al. [63]	CP CML/controls	PBMC	CD4/CD25/CD127/CD62L/FoxP3	Lower in patients in complete cytogenetic response	Enhanced proliferative response to purified protein derivative	Not evaluated
Nadal et al. [64]	CP CML/controls	PBMC	CD4/CD25/CD127/FoxP3/CTLA-4	Higher frequencies after transplant than normal controls and newly diagnosed patients	Purified Tregs from SCT patients had a more potent suppressive activity than those from healthy volunteers	Not evaluated

CP: chronic phase; BM: bone marrow; IM: imatinib; PB: peripheral blood; PBMC; peripheral blood mononuclear cells; BM: bone marrow; SCT: stem cell transplant; IM: imatinib; TKI: tyrosine kinase inhibitor.